Discovering novel therapies for mitochondria related disease

Latest News

Listen to Professor Mike Murphy of the MTG discussing Free Radicals in the Radio 4 programme 'In Our Time'

(Original Airdate - 1st Nov 2018)

Free Radicals - In Our Time (Featuring Mike Murphy)
00:00 / 00:00

Prof. Mike Murphy

MRC Mitochondrial Biology Unit

Dr Thomas Krieg

University of Cambridge,

Department of Medicine



Dr Richard Hartley

University of Glascow, School of Chemistry

Dr Kourosh Saeb-Parsy

University of Cambridge,

Department of Surgery

Dr Christian Frezza

MRC Cancer Unit


Mission Statement

The Mitochondrial Therapies Group (MTG) brings together chemists, biochemists and clinicians to enable rational design, synthesis and testing of novel diagnostic and therapeutic compounds that target mitochondria. Our aim is to use these compounds to understand and prevent common pathologies where mitochondrial dysfunction occurs such as ischaemia-reperfusion (IR) injury, cancer, diabetes and inflammatory disorders. Compounds that the MTG has developed have had notable success in limiting IR injury in in vivo models of heart attack, organ transplantation and stroke. Although we aim to understand the underlying pathology the MTG is focused on translational research that can bring novel therapies from bench to bedside in a timely fashion for disorders that affect our ageing populations.

Work flow



MRC Mitochondrial Biology Unit
Wellcome Trust / MRC Building
Cambridge Biomedical Campus
Hills Road